WuXi Pharmatech (Cayman) Inc. ADS WX Company Overview
Wuxi PharmaTech (Cayman), Inc. is engaged in the provision of research and development outsourcing services for the pharmaceutical, biotechnology, and medical device industries. It operates through the Laboratory Services and Manufacturing Services segments. The Laboratory Services segment offers pharmaceutical and biotech services including discovery and medicinal chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation and toxicology laboratory services, as well as testing services for biologics, medical devices and combination products. The Manufacturing Services segment involves the production of intermediates and active pharmaceutical ingredients for or preclinical and clinical trials of small-molecule and commercial products; and biologics. The company was founded by Ge Li, Xiao Zhong Liu, Zhao Hui Zhang, and Ning Zhao in 2000 and is headquartered in Shanghai, China.
WX Last Price: 30.29
Last Updated: October 26, 2013 11:53 AM
WX Stock Message Board and Forum http://investorshangout.com/search?q=WX&t...mp;yt0=Go!
WuXi Pharmatech (Cayman) Inc. ADS WX Officers and Executives
Name Age Officer Since Title
Dr. Ge Li 47 2000 Chairman & Chief Executive Officer
Mr. Edward Hu 51 2007 Chief Financial & Operating Officer
Dr. Shu Hui Chen 50 2004 Chief Scientific Officer
Mr. Alexander Fowkes - 2012 Vice President-Development
Mr. Xiao Zhong Liu 50 2000 Director & Executive Vice President
Wuxi PharmaTech (Cayman) Inc.
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai, Shanghai 200131
Phone
86 2150461111
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$499.86M
Net Income
$86.58M
2012 Sales Growth
22.8%
Employees
6,817
Annual Report Below for WX
WuXi Pharmatech (Cayman) Inc. ADS WX Recent Headlines
MarketWatch News on WX
Julian Robertson's 5 small cap picks 12:09 p.m. June 25, 2013 - Insider Monkey
OfficeMax investor Neuberger wants more returns 6:41 p.m. June 18, 2012 - MarketWatch.com
WuXi Pharmatech quarterly profit rises 5:13 p.m. May 10, 2011 - MarketWatch.com
Charles River ends plan to buy WuXi Pharma Tech 8:22 a.m. July 30, 2010 - Robert Daniel
Monday's biggest gaining and declining stocks 4:28 p.m. April 26, 2010 - MarketWatch
WuXi agrees to Charles River's $1.6 billion bid 2:48 a.m. April 26, 2010 - Robert Daniel
Stocks in focus for Friday 8:07 p.m. Jan. 3, 2008 - MarketWatch
WuXi PharmaTech names Edward Hu chief operating officer 5:36 p.m. Jan. 3, 2008 - Wallace Witkowski
WuXi PharmaTech to buy AppTec Laboratory for $151 mln 5:33 p.m. Jan. 3, 2008 - Wallace Witkowski
Baidu.com's CFO, Shawn Wang, dies in accident in China 1:34 a.m. Dec. 31, 2007 - MarketWatch
Tuesday's biggest gaining and declining stocks 5:38 p.m. Nov. 13, 2007 - MarketWatch
Wall Street rally, Vodafone Group lead shares up 3% 5:09 p.m. Nov. 13, 2007 - Carla Mozee
Stocks in focus for Tuesday 8:12 p.m. Nov. 12, 2007 - MarketWatch
WuXi PharmaTech Q3 net rev $34 mln vs $19.2 mln 5:19 p.m. Nov. 12, 2007 - Sue Chang
WuXi PharmaTech Q3 net profit 12c vs 5c per ADS 5:18 p.m. Nov. 12, 2007 - Sue Chang
Chinese IPOs thrive despite global credit woes 7:00 p.m. Aug. 12, 2007 - Paul Waide
Updates, advisories and surprises 6:31 p.m. Aug. 9, 2007 - MarketWatch
Thursday's biggest stock gainers and decliners 6:07 p.m. Aug. 9, 2007 - MarketWatch
VMware boosts IPO price despite market swoon 12:24 p.m. Aug. 9, 2007 - Steve Gelsi
WuXi Pharma IPO rallies more than 30% in debut 10:06 a.m. Aug. 9, 2007 - Steve Gelsi
Elan Narrows Q3 Loss - Analyst Blog 11:10 a.m. Oct. 25, 2013 - Zacks.com
First Week Of WX June 2014 Options Trading 11:27 a.m. Oct. 22, 2013 - TheStreet.com
China Biotech In Review: WuXi Laboratory The Only CLIA-Certified Clinical Lab In China 3:45 a.m. Oct. 20, 2013 - Seeking Alpha
Trade-Ideas: WuXi PharmaTech (WX) Is Today's "Dead Cat Bounce" Stock 2:21 p.m. Oct. 15, 2013 - TheStreet.com
Parexel Stock Rises As Analyst Upgrades, Touts CROs 11:25 a.m. Oct. 4, 2013 - Investors Business Daily
Bull’s Eye Report: Parexel (PRXL) 7:01 a.m. Sept. 19, 2013 - InvestorPlace.com
Pipeline Progress at Elan - Analyst Blog 1:30 p.m. Sept. 4, 2013 - Zacks.com
Can the Recent Uptrend Continue for WuXi PharmaTech (Cayman) Inc. (WX)? - Tale of the Tape 7:23 a.m. Aug. 23, 2013 - Zacks.com
WuXi PharmaTech: The Beneficiary Of Biotech Growth 8:26 a.m. Aug. 22, 2013 - Seeking Alpha
China Biotech In Review: Teva Aiming At China, Brazil As Next Targets For Global Expansion 3:33 a.m. Aug. 18, 2013 - Seeking Alpha
WuXi PharmaTech (Cayman) Management Discusses Q2 2013 Results - Earnings Call Transcript 12:01 p.m. Aug. 13, 2013 - Seeking Alpha
UPDATE: Oppenheimer Raises PT on WuXi PharmaTech Following Strong 2Q13 Beat 9:55 a.m. Aug. 13, 2013 - benzinga.com
UPDATE: Jefferies Raises PT on WuXi PharmaTech Following Raised 2013 EPS Guidance 7:40 a.m. Aug. 13, 2013 - benzinga.com
Columbia Management's Top 5 New Buys with Positive Outlook 6:05 p.m. Aug. 12, 2013 - GuruFocus.com
Chinese Small Caps Down But Outperforming Large Caps 4:43 p.m. Aug. 9, 2013 - Investors Business Daily
China Biotech In Review: China's Rx Market To Total $315 Billion In 2020 2:35 a.m. Aug. 4, 2013 - Seeking Alpha
Corcept Makes Ties with Idis - Analyst Blog 6:35 p.m. July 25, 2013 - Zacks.com
Narrower-than-Expected Loss at InterMune - Analyst Blog 5:29 p.m. July 25, 2013 - Zacks.com
Earnings Beat at Alexion, View Upped - Analyst Blog 2:01 p.m. July 25, 2013 - Zacks.com
Breakeven Earnings at Elan - Analyst Blog 9:40 a.m. July 25, 2013 - Zacks.com
Press Releases on WX
WuXi AppTec Receives CLIA Certification for its Genomics Clinical Laboratory 11:38 a.m. Oct. 16, 2013 - PR Newswire
WuXi PharmaTech Schedules Third-Quarter 2013 Earnings Release 10:24 a.m. Oct. 14, 2013 - PR Newswire
Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius, WuXi, Quintiles, and ICON 8:00 a.m. Aug. 15, 2013 - PR Newswire
WuXi PharmaTech Announces Second-Quarter 2013 Results 4:30 p.m. Aug. 12, 2013 - PR Newswire
WuXiPRA Names James Pusey President and General Manager 7:00 a.m. July 16, 2013 - PR Newswire
WuXi PharmaTech Schedules Second-Quarter 2013 Earnings Release 7:00 a.m. July 15, 2013 - PR Newswire
Innovative Technologies that Yield Improved Treatments - Research Report on Mettler-Toledo, Ironwood, Covance, Teleflex and WuXi 8:00 a.m. June 26, 2013 - PR Newswire
Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer 8:00 a.m. June 17, 2013 - PR Newswire
Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer 11:05 p.m. June 16, 2013 - PR Newswire
/C O R R E C T I O N -- WuXi PharmaTech (Cayman) Inc./ 6:47 p.m. May 13, 2013 - PR Newswire
WuXi PharmaTech Announces First-Quarter 2013 Results 4:30 p.m. May 13, 2013 - PR Newswire
WuXi PharmaTech Files 2012 Annual Report on Form 20-F 9:46 a.m. April 17, 2013 - PR Newswire
WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release 11:35 a.m. April 10, 2013 - PR Newswire
Chinese Premier Li Keqiang Visits WuXi PharmaTech's Headquarter in Shanghai 7:29 a.m. April 1, 2013 - PR Newswire
WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary" 9:49 a.m. March 13, 2013 - PR Newswire
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program 5:30 p.m. March 7, 2013 - PR Newswire
WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies 9:00 a.m. March 5, 2013 - BusinessWire
WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies 9:00 a.m. March 5, 2013 - PR Newswire
WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release 12:39 p.m. Feb. 8, 2013 - PR Newswire
WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards 4:56 p.m. Jan. 30, 2013 - PR Newswire
Valuation
P/E Current
25.38
P/E Ratio (with extraordinary items)
22.67
P/E Ratio (without extraordinary items)
13.13
Price to Sales Ratio
2.24
Price to Book Ratio
1.91
Price to Cash Flow Ratio
8.75
Enterprise Value to EBITDA
9.71
Enterprise Value to Sales
2.40
Total Debt to Enterprise Value
0.07
Efficiency
Revenue/Employee
0.07
Income Per Employee
0.01
Receivables Turnover
5.80
Total Asset Turnover
0.71
Liquidity
Current Ratio
2.69
Quick Ratio
2.36
Cash Ratio
1.58
Profitability
Gross Margin
36.65
Operating Margin
17.89
Pretax Margin
20.80
Net Margin
17.32
Return on Assets
12.31
Return on Equity
15.97
Return on Total Capital
14.25
Return on Invested Capital
15.87
Capital Structure
Total Debt to Total Equity
11.20
Total Debt to Total Capital
10.08
Total Debt to Total Assets
8.72
Long-Term Debt to Equity
0.99
Long-Term Debt to Total Capital
0.89
WuXi Pharmatech (Cayman) Inc. ADS WX Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 253.43M 270.04M 334.06M 407.12M 499.86M
Cost of Goods Sold (COGS) incl. D&A 157.11M 161.63M 206.47M 250.7M 316.64M
COGS excluding D&A 126.08M 137.62M 177.26M 216.7M 274.98M
Depreciation & Amortization Expense 31.03M 24M 29.21M 33.99M 41.67M
Depreciation 16.38M 20.4M 25.91M 31.89M 39.17M
Amortization of Intangibles 14.65M 3.6M 3.3M 2.1M 2.5M
Gross Income 96.32M 108.41M 127.59M 156.42M 183.22M
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 56.76M 56.28M 56.09M 72.62M 93.79M
Research & Development - - 0 - 8.14M
Other SG&A 56.76M 56.28M 56.09M 72.62M 85.65M
Other Operating Expense 0 0 0 0 0
Unusual Expense 60.67M (3.6M) 0 (4.71M) (5.31M)
EBIT after Unusual Expense (60.67M) 3.6M 0 4.71M 5.31M
Non Operating Income/Expense 1.23M 3.18M 28.41M 3.8M 3.21M
Non-Operating Interest Income 2.31M 1.13M 1.58M 6.06M 7.73M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 1.39M 1.07M 436,000 789,881 1.72M
Gross Interest Expense 1.39M 1.07M 436,000 789,881 1.72M
Interest Capitalized 0 - 0 0 0
Pretax Income (18.96M) 58.97M 101.06M 97.57M 103.97M
Income Tax (4.02M) 5.53M 10.24M 16.6M 17.39M
Income Tax - Current Domestic 6.19M 8.29M 9.99M 14.11M 14.61M
Income Tax - Current Foreign 790,922 59,004 106,000 205,969 152,986
Income Tax - Deferred Domestic (235,310) (1.92M) (1.65M) (1.29M) (1.38M)
Income Tax - Deferred Foreign (10.77M) (896,061) 1.8M 3.58M 4M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (14.95M) 53.44M 90.81M 80.97M 86.58M
Minority Interest Expense 0 0 0 0 0
Net Income (14.95M) 53.44M 90.81M 80.97M 86.58M
Extraordinaries & Discontinued Operations (49.24M) (558,038) 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (49.24M) (558,038) 0 0 0
Net Income After Extraordinaries (64.19M) 52.88M 90.81M 80.97M 86.58M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (14.95M) 53.44M 90.81M 80.97M 86.58M
EPS (Basic) (1.04) 0.80 1.28 1.12 1.20
Basic Shares Outstanding 63.78M 67.99M 69.54M 70.88M 71.05M
EPS (Diluted) (1.04) 0.72 1.20 1.04 1.20
Diluted Shares Outstanding 63.78M 73.65M 74.69M 75.44M 72.8M
EBITDA 70.59M 76.13M 100.71M 117.79M 131.1M
WuXi Pharmatech (Cayman) Inc. ADS WX Filings
SEC Filings for WuXi Pharmatech (Cayman) Inc. ADS
Filing Date Document Date Type Category Amended
02/14/2013 N/A SC 13G Institutional Ownership
02/14/2013 N/A SC 13G/A Institutional Ownership *
01/23/2013 N/A SC 13G/A Institutional Ownership *
07/30/2012 N/A S-8 Registration Statement
02/14/2012 N/A SC 13G/A Institutional Ownership *
02/14/2012 N/A SC 13G/A Institutional Ownership *
02/10/2012 N/A SC 13G/A Institutional Ownership *
01/27/2012 N/A SC 13G Institutional Ownership
02/14/2011 N/A SC 13G/A Institutional Ownership *
02/14/2011 N/A SC 13G/A Institutional Ownership *
02/11/2011 N/A SC 13G/A Institutional Ownership *
11/16/2010 N/A SC 13D/A N/A *
11/15/2010 N/A SC 13G Institutional Ownership
11/10/2010 N/A SC 13G/A Institutional Ownership *
08/02/2010 N/A SC 13D/A N/A *
06/03/2010 N/A SC 13G/A Institutional Ownership *
05/05/2010 N/A SC 13D N/A
04/27/2010 N/A SC 13D/A N/A *
02/16/2010 N/A SC 13G/A Institutional Ownership *
02/12/2010 N/A SC 13G Institutional Ownership
SEC Filings provided by EDGAR Online, Inc.
WuXi Pharmatech (Cayman) Inc. ADS WX Insider Actions
WX WuXi Pharmatech (Cayman) Inc. ADS Research Links
Stock Message Board http://investorshangout.com/search?q=WX&t...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/WX/quote
Stock Chart http://www.otcmarkets.com/stock/WX/chart
Company Info http://www.otcmarkets.com/stock/WX/company-info
Recent News http://www.otcmarkets.com/stock/WX/news
Financials http://www.otcmarkets.com/stock/WX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/WX/filings
Short Sales http://www.otcmarkets.com/stock/WX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/WX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/WX/research
Summary http://finance.yahoo.com/q?s=WX
Historical Prices http://finance.yahoo.com/q/hp?s=WX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=WX
Basic Chart http://finance.yahoo.com/q/bc?s=WX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=WX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=WX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=WX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=WX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=WX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=WX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=WX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=WX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=WX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=WX
Balance Sheet http://finance.yahoo.com/q/bs?s=WX
Cash Flow http://finance.yahoo.com/q/cf?s=WX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/WX
Market Watch http://www.marketwatch.com/investing/stock/WX
Bloomberg http://www.bloomberg.com/quote/WX:US
Morningstar http://quotes.morningstar.com/stock/s?t=WX
Bussinessweek http://investing.businessweek.com/research/st...?ticker=WX
Barchart http://www.barchart.com/quotes/stocks/WX
OTC Short Report http://otcshortreport.com/index.php?index=WX
Investopedia http://www.investopedia.com/markets/stocks/WX/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Wuxi PharmaTech (Cayman), Inc. is engaged in the provision of research and development outsourcing services for the pharmaceutical, biotechnology, and medical device industries. It operates through the Laboratory Services and Manufacturing Services segments. The Laboratory Services segment offers pharmaceutical and biotech services including discovery and medicinal chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation and toxicology laboratory services, as well as testing services for biologics, medical devices and combination products. The Manufacturing Services segment involves the production of intermediates and active pharmaceutical ingredients for or preclinical and clinical trials of small-molecule and commercial products; and biologics. The company was founded by Ge Li, Xiao Zhong Liu, Zhao Hui Zhang, and Ning Zhao in 2000 and is headquartered in Shanghai, China.
WX Last Price: 30.29
Last Updated: October 26, 2013 11:53 AM
WX Stock Message Board and Forum http://investorshangout.com/search?q=WX&t...mp;yt0=Go!
WuXi Pharmatech (Cayman) Inc. ADS WX Officers and Executives
Name Age Officer Since Title
Dr. Ge Li 47 2000 Chairman & Chief Executive Officer
Mr. Edward Hu 51 2007 Chief Financial & Operating Officer
Dr. Shu Hui Chen 50 2004 Chief Scientific Officer
Mr. Alexander Fowkes - 2012 Vice President-Development
Mr. Xiao Zhong Liu 50 2000 Director & Executive Vice President
Wuxi PharmaTech (Cayman) Inc.
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai, Shanghai 200131
Phone
86 2150461111
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$499.86M
Net Income
$86.58M
2012 Sales Growth
22.8%
Employees
6,817
Annual Report Below for WX
WuXi Pharmatech (Cayman) Inc. ADS WX Recent Headlines
MarketWatch News on WX
Julian Robertson's 5 small cap picks 12:09 p.m. June 25, 2013 - Insider Monkey
OfficeMax investor Neuberger wants more returns 6:41 p.m. June 18, 2012 - MarketWatch.com
WuXi Pharmatech quarterly profit rises 5:13 p.m. May 10, 2011 - MarketWatch.com
Charles River ends plan to buy WuXi Pharma Tech 8:22 a.m. July 30, 2010 - Robert Daniel
Monday's biggest gaining and declining stocks 4:28 p.m. April 26, 2010 - MarketWatch
WuXi agrees to Charles River's $1.6 billion bid 2:48 a.m. April 26, 2010 - Robert Daniel
Stocks in focus for Friday 8:07 p.m. Jan. 3, 2008 - MarketWatch
WuXi PharmaTech names Edward Hu chief operating officer 5:36 p.m. Jan. 3, 2008 - Wallace Witkowski
WuXi PharmaTech to buy AppTec Laboratory for $151 mln 5:33 p.m. Jan. 3, 2008 - Wallace Witkowski
Baidu.com's CFO, Shawn Wang, dies in accident in China 1:34 a.m. Dec. 31, 2007 - MarketWatch
Tuesday's biggest gaining and declining stocks 5:38 p.m. Nov. 13, 2007 - MarketWatch
Wall Street rally, Vodafone Group lead shares up 3% 5:09 p.m. Nov. 13, 2007 - Carla Mozee
Stocks in focus for Tuesday 8:12 p.m. Nov. 12, 2007 - MarketWatch
WuXi PharmaTech Q3 net rev $34 mln vs $19.2 mln 5:19 p.m. Nov. 12, 2007 - Sue Chang
WuXi PharmaTech Q3 net profit 12c vs 5c per ADS 5:18 p.m. Nov. 12, 2007 - Sue Chang
Chinese IPOs thrive despite global credit woes 7:00 p.m. Aug. 12, 2007 - Paul Waide
Updates, advisories and surprises 6:31 p.m. Aug. 9, 2007 - MarketWatch
Thursday's biggest stock gainers and decliners 6:07 p.m. Aug. 9, 2007 - MarketWatch
VMware boosts IPO price despite market swoon 12:24 p.m. Aug. 9, 2007 - Steve Gelsi
WuXi Pharma IPO rallies more than 30% in debut 10:06 a.m. Aug. 9, 2007 - Steve Gelsi
Elan Narrows Q3 Loss - Analyst Blog 11:10 a.m. Oct. 25, 2013 - Zacks.com
First Week Of WX June 2014 Options Trading 11:27 a.m. Oct. 22, 2013 - TheStreet.com
China Biotech In Review: WuXi Laboratory The Only CLIA-Certified Clinical Lab In China 3:45 a.m. Oct. 20, 2013 - Seeking Alpha
Trade-Ideas: WuXi PharmaTech (WX) Is Today's "Dead Cat Bounce" Stock 2:21 p.m. Oct. 15, 2013 - TheStreet.com
Parexel Stock Rises As Analyst Upgrades, Touts CROs 11:25 a.m. Oct. 4, 2013 - Investors Business Daily
Bull’s Eye Report: Parexel (PRXL) 7:01 a.m. Sept. 19, 2013 - InvestorPlace.com
Pipeline Progress at Elan - Analyst Blog 1:30 p.m. Sept. 4, 2013 - Zacks.com
Can the Recent Uptrend Continue for WuXi PharmaTech (Cayman) Inc. (WX)? - Tale of the Tape 7:23 a.m. Aug. 23, 2013 - Zacks.com
WuXi PharmaTech: The Beneficiary Of Biotech Growth 8:26 a.m. Aug. 22, 2013 - Seeking Alpha
China Biotech In Review: Teva Aiming At China, Brazil As Next Targets For Global Expansion 3:33 a.m. Aug. 18, 2013 - Seeking Alpha
WuXi PharmaTech (Cayman) Management Discusses Q2 2013 Results - Earnings Call Transcript 12:01 p.m. Aug. 13, 2013 - Seeking Alpha
UPDATE: Oppenheimer Raises PT on WuXi PharmaTech Following Strong 2Q13 Beat 9:55 a.m. Aug. 13, 2013 - benzinga.com
UPDATE: Jefferies Raises PT on WuXi PharmaTech Following Raised 2013 EPS Guidance 7:40 a.m. Aug. 13, 2013 - benzinga.com
Columbia Management's Top 5 New Buys with Positive Outlook 6:05 p.m. Aug. 12, 2013 - GuruFocus.com
Chinese Small Caps Down But Outperforming Large Caps 4:43 p.m. Aug. 9, 2013 - Investors Business Daily
China Biotech In Review: China's Rx Market To Total $315 Billion In 2020 2:35 a.m. Aug. 4, 2013 - Seeking Alpha
Corcept Makes Ties with Idis - Analyst Blog 6:35 p.m. July 25, 2013 - Zacks.com
Narrower-than-Expected Loss at InterMune - Analyst Blog 5:29 p.m. July 25, 2013 - Zacks.com
Earnings Beat at Alexion, View Upped - Analyst Blog 2:01 p.m. July 25, 2013 - Zacks.com
Breakeven Earnings at Elan - Analyst Blog 9:40 a.m. July 25, 2013 - Zacks.com
Press Releases on WX
WuXi AppTec Receives CLIA Certification for its Genomics Clinical Laboratory 11:38 a.m. Oct. 16, 2013 - PR Newswire
WuXi PharmaTech Schedules Third-Quarter 2013 Earnings Release 10:24 a.m. Oct. 14, 2013 - PR Newswire
Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius, WuXi, Quintiles, and ICON 8:00 a.m. Aug. 15, 2013 - PR Newswire
WuXi PharmaTech Announces Second-Quarter 2013 Results 4:30 p.m. Aug. 12, 2013 - PR Newswire
WuXiPRA Names James Pusey President and General Manager 7:00 a.m. July 16, 2013 - PR Newswire
WuXi PharmaTech Schedules Second-Quarter 2013 Earnings Release 7:00 a.m. July 15, 2013 - PR Newswire
Innovative Technologies that Yield Improved Treatments - Research Report on Mettler-Toledo, Ironwood, Covance, Teleflex and WuXi 8:00 a.m. June 26, 2013 - PR Newswire
Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer 8:00 a.m. June 17, 2013 - PR Newswire
Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer 11:05 p.m. June 16, 2013 - PR Newswire
/C O R R E C T I O N -- WuXi PharmaTech (Cayman) Inc./ 6:47 p.m. May 13, 2013 - PR Newswire
WuXi PharmaTech Announces First-Quarter 2013 Results 4:30 p.m. May 13, 2013 - PR Newswire
WuXi PharmaTech Files 2012 Annual Report on Form 20-F 9:46 a.m. April 17, 2013 - PR Newswire
WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release 11:35 a.m. April 10, 2013 - PR Newswire
Chinese Premier Li Keqiang Visits WuXi PharmaTech's Headquarter in Shanghai 7:29 a.m. April 1, 2013 - PR Newswire
WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary" 9:49 a.m. March 13, 2013 - PR Newswire
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program 5:30 p.m. March 7, 2013 - PR Newswire
WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies 9:00 a.m. March 5, 2013 - BusinessWire
WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies 9:00 a.m. March 5, 2013 - PR Newswire
WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release 12:39 p.m. Feb. 8, 2013 - PR Newswire
WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards 4:56 p.m. Jan. 30, 2013 - PR Newswire
Valuation
P/E Current
25.38
P/E Ratio (with extraordinary items)
22.67
P/E Ratio (without extraordinary items)
13.13
Price to Sales Ratio
2.24
Price to Book Ratio
1.91
Price to Cash Flow Ratio
8.75
Enterprise Value to EBITDA
9.71
Enterprise Value to Sales
2.40
Total Debt to Enterprise Value
0.07
Efficiency
Revenue/Employee
0.07
Income Per Employee
0.01
Receivables Turnover
5.80
Total Asset Turnover
0.71
Liquidity
Current Ratio
2.69
Quick Ratio
2.36
Cash Ratio
1.58
Profitability
Gross Margin
36.65
Operating Margin
17.89
Pretax Margin
20.80
Net Margin
17.32
Return on Assets
12.31
Return on Equity
15.97
Return on Total Capital
14.25
Return on Invested Capital
15.87
Capital Structure
Total Debt to Total Equity
11.20
Total Debt to Total Capital
10.08
Total Debt to Total Assets
8.72
Long-Term Debt to Equity
0.99
Long-Term Debt to Total Capital
0.89
WuXi Pharmatech (Cayman) Inc. ADS WX Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 253.43M 270.04M 334.06M 407.12M 499.86M
Cost of Goods Sold (COGS) incl. D&A 157.11M 161.63M 206.47M 250.7M 316.64M
COGS excluding D&A 126.08M 137.62M 177.26M 216.7M 274.98M
Depreciation & Amortization Expense 31.03M 24M 29.21M 33.99M 41.67M
Depreciation 16.38M 20.4M 25.91M 31.89M 39.17M
Amortization of Intangibles 14.65M 3.6M 3.3M 2.1M 2.5M
Gross Income 96.32M 108.41M 127.59M 156.42M 183.22M
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 56.76M 56.28M 56.09M 72.62M 93.79M
Research & Development - - 0 - 8.14M
Other SG&A 56.76M 56.28M 56.09M 72.62M 85.65M
Other Operating Expense 0 0 0 0 0
Unusual Expense 60.67M (3.6M) 0 (4.71M) (5.31M)
EBIT after Unusual Expense (60.67M) 3.6M 0 4.71M 5.31M
Non Operating Income/Expense 1.23M 3.18M 28.41M 3.8M 3.21M
Non-Operating Interest Income 2.31M 1.13M 1.58M 6.06M 7.73M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 1.39M 1.07M 436,000 789,881 1.72M
Gross Interest Expense 1.39M 1.07M 436,000 789,881 1.72M
Interest Capitalized 0 - 0 0 0
Pretax Income (18.96M) 58.97M 101.06M 97.57M 103.97M
Income Tax (4.02M) 5.53M 10.24M 16.6M 17.39M
Income Tax - Current Domestic 6.19M 8.29M 9.99M 14.11M 14.61M
Income Tax - Current Foreign 790,922 59,004 106,000 205,969 152,986
Income Tax - Deferred Domestic (235,310) (1.92M) (1.65M) (1.29M) (1.38M)
Income Tax - Deferred Foreign (10.77M) (896,061) 1.8M 3.58M 4M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (14.95M) 53.44M 90.81M 80.97M 86.58M
Minority Interest Expense 0 0 0 0 0
Net Income (14.95M) 53.44M 90.81M 80.97M 86.58M
Extraordinaries & Discontinued Operations (49.24M) (558,038) 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (49.24M) (558,038) 0 0 0
Net Income After Extraordinaries (64.19M) 52.88M 90.81M 80.97M 86.58M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (14.95M) 53.44M 90.81M 80.97M 86.58M
EPS (Basic) (1.04) 0.80 1.28 1.12 1.20
Basic Shares Outstanding 63.78M 67.99M 69.54M 70.88M 71.05M
EPS (Diluted) (1.04) 0.72 1.20 1.04 1.20
Diluted Shares Outstanding 63.78M 73.65M 74.69M 75.44M 72.8M
EBITDA 70.59M 76.13M 100.71M 117.79M 131.1M
WuXi Pharmatech (Cayman) Inc. ADS WX Filings
SEC Filings for WuXi Pharmatech (Cayman) Inc. ADS
Filing Date Document Date Type Category Amended
02/14/2013 N/A SC 13G Institutional Ownership
02/14/2013 N/A SC 13G/A Institutional Ownership *
01/23/2013 N/A SC 13G/A Institutional Ownership *
07/30/2012 N/A S-8 Registration Statement
02/14/2012 N/A SC 13G/A Institutional Ownership *
02/14/2012 N/A SC 13G/A Institutional Ownership *
02/10/2012 N/A SC 13G/A Institutional Ownership *
01/27/2012 N/A SC 13G Institutional Ownership
02/14/2011 N/A SC 13G/A Institutional Ownership *
02/14/2011 N/A SC 13G/A Institutional Ownership *
02/11/2011 N/A SC 13G/A Institutional Ownership *
11/16/2010 N/A SC 13D/A N/A *
11/15/2010 N/A SC 13G Institutional Ownership
11/10/2010 N/A SC 13G/A Institutional Ownership *
08/02/2010 N/A SC 13D/A N/A *
06/03/2010 N/A SC 13G/A Institutional Ownership *
05/05/2010 N/A SC 13D N/A
04/27/2010 N/A SC 13D/A N/A *
02/16/2010 N/A SC 13G/A Institutional Ownership *
02/12/2010 N/A SC 13G Institutional Ownership
SEC Filings provided by EDGAR Online, Inc.
WuXi Pharmatech (Cayman) Inc. ADS WX Insider Actions
WX WuXi Pharmatech (Cayman) Inc. ADS Research Links
Stock Message Board http://investorshangout.com/search?q=WX&t...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/WX/quote
Stock Chart http://www.otcmarkets.com/stock/WX/chart
Company Info http://www.otcmarkets.com/stock/WX/company-info
Recent News http://www.otcmarkets.com/stock/WX/news
Financials http://www.otcmarkets.com/stock/WX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/WX/filings
Short Sales http://www.otcmarkets.com/stock/WX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/WX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/WX/research
Summary http://finance.yahoo.com/q?s=WX
Historical Prices http://finance.yahoo.com/q/hp?s=WX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=WX
Basic Chart http://finance.yahoo.com/q/bc?s=WX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=WX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=WX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=WX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=WX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=WX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=WX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=WX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=WX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=WX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=WX
Balance Sheet http://finance.yahoo.com/q/bs?s=WX
Cash Flow http://finance.yahoo.com/q/cf?s=WX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/WX
Market Watch http://www.marketwatch.com/investing/stock/WX
Bloomberg http://www.bloomberg.com/quote/WX:US
Morningstar http://quotes.morningstar.com/stock/s?t=WX
Bussinessweek http://investing.businessweek.com/research/st...?ticker=WX
Barchart http://www.barchart.com/quotes/stocks/WX
OTC Short Report http://otcshortreport.com/index.php?index=WX
Investopedia http://www.investopedia.com/markets/stocks/WX/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
